Demographic, Clinical, Financial Factors Tied to GLP-1 Agonist Discontinuation
By Lori Solomon HealthDay Reporter
WEDNESDAY, May 29, 2024 -- Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor agonist discontinuation, according to a research letter published online May 24 in JAMA Network Open.
Duy Do, Ph.D., from the Evernorth Research Institute in St. Louis, and colleagues estimated the prevalence of GLP-1 agonist discontinuation among new users with type 2 diabetes or obesity and the patient characteristics associated with discontinuation. Analysis included data from 195,915 adults with continuous health insurance enrollment and 17 months of follow-up identified through the Komodo Healthcare Map database.
The researchers found that the overall prevalence of GLP-1 agonist discontinuation was 26.2 percent at three months, 30.8 percent at six months, and 36.5 percent at 12 months. There was a higher prevalence of discontinuation for patients with obesity at 12 months, compared to those with type 2 diabetes only or those with both (50.3, 35.8, and 34.2 percent, respectively). Higher odds of discontinuation at 12 months were seen among patients who were Black or Hispanic, male, and Medicare or Medicaid enrollees; lived in areas with very high levels of social needs; had obesity only, heart failure, or other cardiovascular conditions at baseline; and had new gastrointestinal adverse effects at follow-up. Lower odds of discontinuation were seen among older versus younger patients. Each one-percentage point increase in out-of-pocket cost per a 30-day supply of GLP-1 agonist was associated with increased odds of discontinuation (odds ratio, 1.02).
"Discontinuation could have policy and medication coverage implications, especially if the weight reduction is not sustained after medications are discontinued," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2024
Read this next
In Pediatric Leukemia, Survival Linked to Duration of Overweight, Obesity
TUESDAY, May 20, 2025 -- For children with acute lymphoblastic leukemia (ALL), longer duration of overweight or obesity is associated with lower overall and event-free survival...
GLP-1 Receptor Agonists Not Linked to Increased Risk of Psychiatric Adverse Events, Depression
MONDAY, May 19, 2025 -- For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased...
Risk of Obesity-Related Cancer Similar for GLP-1 Receptor Agonists and Bariatric Surgery
THURSDAY, May 15, 2025 -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.